Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bone Marrow Aplasia
- Hematologic Malignancy
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Platelet Refractoriness
- Thrombocytopenia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Dose Ranging MultidoseMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04631211
- Collaborators
- Department of Health and Human Services
- Investigators
- Principal Investigator: Terry Gernsheimer, MD University of Washington Study Director: Mike Fitzpatrick, PhD Cellphire, Inc.